Printer Friendly

Hoffmann-La Roche obtains United States patent.

Hoffmann-La Roche Inc. (Nutley, NJ) has patented a novel cytokine protein called IL-12 or Cytotoxic Lymphocyte Maturation Factor (CLMF) produced and synthesized by human NC-37 B lymphoblastoid cells. CLMF synergistically induces with low concentrations of IL-2 the cytolytic activity of Lymphokine Activated Killer (LAK) cells, and CLMF is capable of stimulating T-cell growth. Also claimed are the cloned gene for CLMF, its recombination in a suitable vector, the transformed cells containing said vector, the recombinant protein produced by the transformed cells and antibodies to CLMF. (US 6,683,046)
COPYRIGHT 2004 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:BIOTECH Patent News
Article Type:Brief Article
Geographic Code:1USA
Date:Feb 1, 2004
Words:89
Previous Article:Texas A&M obtains United States patent.
Next Article:Tokai University obtains United States patent.
Topics:


Related Articles
CURAGEN GETS PATENTS ON INTERACTIONS IMPLICATED IN CANCER.
Ribapharm sues Hoffmann-La Roche in Germany over ribavirin patent.
Hoffmann-La Roche $1 billion lawsuit filed by Promega.
AMGEN SUES OVER EPOGEN THREE UNITS OF ROCHE ACCUSED OF PATENT INFRINGEMENT.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters